Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 11/20 | 0.61 |
| ▸ | CA2 | P00918 | 8/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.61 |
| ▸ | CA1 | P00915 | 9/20 | 0.54 |
| ▸ | CA7 | P43166 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 6/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15419987 | 0.90 | CA12 (0.58) | CA12CA2CA14CA1CA7 | |
| SCHEMBL1145926 | 0.84 | CA12 (0.63) | CA12CA2CA14CA1CA7 | |
| SCHEMBL20646495 | 0.84 | CA12 (0.63) | CA12CA2CA14CA1CA7 | |
| SCHEMBL18756420 | 0.83 | CA12 (0.61) | CA12CA2CA14CA1CA7 | |
| SCHEMBL19925453 | 0.83 | CA12 (0.61) | CA12CA2CA14CA1CA7 | |
| SCHEMBL19004206 | 0.83 | CA12 (0.61) | CA12CA2CA14CA1CA7 | |
| SCHEMBL23762491 | 0.81 | CA12 (0.59) | CA12CA2CA14CA1CA7 | |
| SCHEMBL22404329 | 0.81 | CA12 (0.59) | CA12CA2CA14CA1CA7 | |
| SCHEMBL22404228 | 0.81 | CA12 (0.59) | CA12CA2CA14CA1CA7 | |
| SCHEMBL14010825 | 0.81 | CA12 (0.64) | CA12CA2CA14CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227339-B2 | Salt form and crystal form of 1,2,5-thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2019-03-12 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20180141940-A1 | SALT FORM AND CRYSTAL FORM OF 1,2,5-THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | JIANGSU KANION PARMACEUTICAL CO. LTD (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| WO-2015165340-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | 南京明德新药研发股份有限公司 | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227339-B2 | Salt form and crystal form of 1,2,5-thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate | SPIN1, SULT1A1, NAP1L1 | CA12 1002/4885CA2 63/4885CA14 881/4885 |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | CA12 3593/4885CA2 1165/4885CA14 3053/4885 |
| US-20180141940-A1 | SALT FORM AND CRYSTAL FORM OF 1,2,5-THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | SPIN1, SULT1A1, NAP1L1 | CA12 1002/4885CA2 63/4885CA14 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.